Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials - 21/08/11
, Robert V. Kelly, MD a, David F. Kong, MD b, Venu Menon, MD a, Monica Shah, MD b, Jorge Ferreira, MD c, Karen S. Pieper, MS b, Douglas Criger, MPH b, Rosana Poggio, MD d, E. Magnus Ohman, MD a, Joel Gore, MD e, Robert M. Califf, MD b, Christopher B. Granger, MD b
Requests for reprints should be addressed to Mauricio G. Cohen, MD, Assistant Professor of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill, 130 Mason Farm Road, CB # 7075, Bioinformatics Building, Suite 4128, Chapel Hill, NC 27599-7075.Abstract |
Purpose |
To correlate pulmonary artery catheterization (PAC) use and 30-day outcomes and to characterize the use of pulmonary artery catheters among patients with acute coronary syndromes (ACS).
Subjects and methods |
We retrospectively studied 26437 ACS patients from two large multicenter, international randomized clinical trials. Multivariable and causal inference analyses were applied to adjust for differences in baseline risk.
Results |
PAC was performed in 735 patients (2.8%), with a median time to insertion of 24 hours. Patients undergoing PAC were older (median, 67 vs. 64 years), more often diabetic (25.7% vs.16.2%), and more likely to present with ST-segment elevation (81.6% vs. 70.2%) or Killip class III or IV (7.9% vs. 1.4%). US patients were 3.8 times more likely than non-US patients to undergo PAC. Patients managed with PAC also underwent more procedures, including percutaneous intervention (40.7% vs. 18.1%), coronary artery bypass grafting (12.5% vs. 7.7%), and endotracheal intubation (29.3% vs. 2.2%). Mortality at 30 days was substantially higher among patients with PAC for both unadjusted (odds ratio [OR] 8.7; 95% confidence interval [CI] 7.3–10.2) and adjusted analyses (OR 6.4; 95% CI 5.4–7.6) in all groups except in patients with cardiogenic shock (OR 0.99; 95% CI 0.80–1.23).
Conclusions |
PAC was associated with increased mortality, both before and after adjustment for baseline patient differences and subsequent events that may have led to PAC use, except in patients with cardiogenic shock. The definitive role of PAC in managing patients with ACS is still to be determined.
Le texte complet de cet article est disponible en PDF.Keywords : Pulmonary artery catheterization, Acute coronary syndrome, GUSTO IIb, GUSTO III
Plan
| The GUSTO IIb study was supported in part by the Guidant Corporation, Redwood City, California, and by Ciba-Geigy, Summit, New Jersey. The GUSTO III study was funded by grants from Centocor, Inc., Malvern, Pennsylvania, and Boehringer-Mannheim, Indianapolis, Indiana, and Mannheim, Germany. |
Vol 118 - N° 5
P. 482-488 - mai 2005 Retour au numéro
Article précédent
- Moving to a slow beat
- Julia H. Indik
- Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study
- Lars Frost, Lone Juul Hune, Peter Vestergaard
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?